Filtered By:
Procedure: Transplants
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 89541 results found since Jan 2013.
Using Haplogictm & Recipient Ancestry: The Likelihood of Identifying an 8/8 HLA-Matched Unrelated Donor Can be Accurately Predicted at the Time of the Preliminary Search Markedly Improving Search Efficiency & Speed to Allograft: An 830 Patient Analysis
Background: As many searches are urgent, a strategy to rapidly& efficiently establish if a suitable unrelated donor (URD) can be identified is needed. The standard URD HLA-match requirement at our center is 8/8 HLA-A,B,C,DRB1 alleles. The National Marrow Donor Program (NMDP) provides a computerized % chance of 8/8& individual locus HLA-match predictions (HapLogic ™) for URDs on the NMDP search based on available HLA-typing& ancestry of the patient (pt)& URD. We hypothesized that the likelihood of an 8/8 URD could be accurately estimated by devising a Search Prognosis Categorization (SPC) based upon the number of potentia...
Source: Biology of Blood and Marrow Transplantation - February 22, 2017 Category: Hematology Authors: Eric Davis, Sean M. Devlin, Candice Cooper, Melissa Nhaissi, Jennifer Paulson, Deborah S. Wells, Andromachi Scaradavou, Sergio A. Giralt, Esperanza B. Papadopoulos, Nancy A. Kernan, Courtney Byam, Juliet N. Barker Source Type: research
Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?
ConclusionsRace, haplotype frequency and disease status at the time of MUD search influence probability to identify a MUD and receive a transplant. Patients with low likelihood to receive a MUD transplant may proceed to a haploidentical transplant as soon as indicated, as this approach does not appear to compromise transplant outcomes.DisclosuresKonopleva: Stemline Therapeutics: Research Funding. Oran: AROG pharmaceuticals: Research Funding; Celgene: Consultancy, Research Funding; ASTEX: Research Funding. Champlin: Otsuka: Research Funding; Sanofi: Research Funding.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ciurea, S. O., Borges Bittencourt, M. C., Milton, D. R., Cao, K., Kongtim, P., Rondon, G., Chen, J., Konopleva, M. Y., Ramos Perez, J. M., Elshazly, M., Aljadayeh, M., Alvarez, M., Im, J. S., Alatrash, G., Mehta, R. S., Popat, U., Bashir, Q., Oran, B., Ho Tags: 732. Clinical Allogeneic Transplantation: Results: Poster II Source Type: research
Frailty in Patients With Hematologic Malignancies and Those Undergoing Transplantation: A Scoping Review
Oncol Nurs Forum. 2021 May 1;48(3):291-307. doi: 10.1188/21.ONF.291-307.ABSTRACTPROBLEM IDENTIFICATION: Although frailty is an important parameter in treatment planning and in predicting prognosis and overall survival among patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation, frailty assessment tools are not standardized in clinical care settings. The purpose of this article is to provide an overview of the literature on frailty assessment tools in these patient populations.LITERATURE SEARCH: A systematic search of CINAHL®, Embase®, MEDLINE®, PubMed®, and Web of Science was ...
Source: Oncology Nursing Forum - April 15, 2021 Category: Nursing Authors: Lathika Mohanraj Lana Sargent Roy Brown Theresa Swift-Scanlan Source Type: research
